1-[(4-甲氧基苯基)-苯基甲基]-哌嗪 | 54041-93-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1-[(4-甲氧基苯基)-苯基甲基]-哌嗪
• 英文名称: 1-(p-Methoxybenzhydryl)piperazine
• 英文别名: 1-(4-methoxy-benzhydryl)-piperazine；1-(4-Methoxy-benzhydryl)-piperazin；1-[(4-methoxyphenyl)phenylmethyl]piperazine；1-[(4-Methoxyphenyl)-phenylmethyl]piperazine
• CAS: 54041-93-9
• 化学式: C₁₈H₂₂N₂O
• 分子量: 282.385
• InChiKey: QEBOYBVMAZLNLX-UHFFFAOYSA-N

物化性质

• 熔点：
  80-81 °C
• 沸点：
  185-190 °C(Press: 0.5 Torr)
• 密度：
  1.087±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-[(4-甲氧基苯基)-苯基甲基]-哌嗪 在 氯甲酸乙酯 作用下， 生成 (E)-N-[4-[4-[(4-methoxyphenyl)-phenylmethyl]piperazin-1-yl]butyl]-3-pyridin-3-ylprop-2-enamide
  参考文献：
  名称：

  Acrylamide derivatives as antiallergic agents. 2. Synthesis and structure activity relationships of N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3-(3-pyridyl)acrylamides

  摘要：

  A new series of 3-(3-pyridyl)acrylamides 16, 17, 19, and 26, and 5-(3-pyridyl)-2,4-pentadienamides 20-25 were prepared and evaluated for their antiallergic activity. Several of these compounds exhibited more potent inhibitory activities than the parent compound 1a [(E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (3-pyridyl)acrylamide] against the rat passive cutaneous anaphylaxis (PCA) reaction and the enzyme 5-lipoxygenase. Particularly, (E)-N-[4-[4-(diphenylmethyl)-1-piperazinyl]butyl]-3- (6-methyl-3-pyridyl)acrylamide (17p) showed an ED50 value of 3.3 mg/kg po in the rat PCA test, which was one-fifth of ketotifen and oxatomide. As compared with ketotifen and oxatomide, compound 17p (AL-3264) possessed a better balance of antiallergic properties due to inhibition of chemical mediator release, inhibition of 5-lipoxygenase, and antagonism of histamine.

  DOI：

  10.1021/jm00123a012
• 作为产物：
  描述：

  哌嗪 、 4-methoxybenzhydryl chloride 在 potassium carbonate 、 potassium iodide 作用下， 以 乙腈 为溶剂， 生成 1-[(4-甲氧基苯基)-苯基甲基]-哌嗪
  参考文献：
  名称：

  Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  摘要：

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.008

文献信息

• [EN] BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS<br/>[FR] DÉRIVÉS BICYCLIQUES DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT D'AFFECTIONS ASSOCIÉES AU RÉCEPTEUR DES ANDROGÈNES
  申请人：ASTRAZENECA AB

  公开号：WO2009081197A1

  公开（公告）日：2009-07-02

  The invention concerns bicyclic compounds of Formula (I), wherein the integers X1, X2, X3, Ring A, R4, R5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  该发明涉及式(I)的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m的定义如描述中所示。本发明还涉及制备这些化合物的方法、含有它们的药物组合物以及它们在制备用于预防或治疗雄激素受体相关疾病的药物中的应用。
• [EN] PROCESS FOR THE PREPARATION OF ROSUVASTATIN<br/>[FR] PROCÉDÉ DE PRÉPARATION DE ROSUVASTATINE
  申请人：KRKA TOVARNA ZDRAVIL D D NOVO

  公开号：WO2010081861A1

  公开（公告）日：2010-07-22

  The invention relates to a process for the preparation of a HMG - CoA reductase inhibitor such as rosuvastatin, as well as intermediates useful in such process. The invention also relates to salts of HMG-CoA reductase inhibitors and processes for preparing same as well as processes for preparing pharmaceutically acceptable salts of HMG-CoA reductase inhibitors.

  该发明涉及一种用于制备类似罗伐他汀的HMG - CoA还原酶抑制剂的过程，以及在该过程中有用的中间体。该发明还涉及HMG-CoA还原酶抑制剂的盐以及制备其的过程，以及制备HMG-CoA还原酶抑制剂的药用可接受盐的过程。
• [EN] PROCESSES FOR PREPARATION OF MONTELUKAST SODIUM AND PURIFICATION OF DIOL INTERMEDIATE<br/>[FR] MÉTHODES DE PRÉPARATION DE MONTÉLUKAST DE SODIUM ET DE PURIFICATION D'UN INTERMÉDIAIRE DIOL
  申请人：IND SWIFT LAB LTD

  公开号：WO2012077133A1

  公开（公告）日：2012-06-14

  A process for preparation of montelukast sodium through novel montelukast amine salts is provided, wherein the amine is selected from 1- (l-naphthyl)ethylamine, S-methyl-L-cysteine, diallylamine or isomers thereof. A process for purification of 2-(2-(3-(S)-(3-(7-chloro-2-quinolinyl)-ethenyl)phenyl)-3-hydroxylpropyl)-phenyl-2-propanol is also provided, which uses a halogenated hydrocarbon and a nitrile as solvent.

  提供一种通过新颖的蒙特鲁卡斯特胺盐制备蒙特鲁卡斯特钠的方法，其中所选的胺来自1-(1-萘基)乙胺，S-甲基-L-半胱氨酸，二烯基胺或其异构体。还提供了一种用卤代烃和腈作为溶剂的纯化2-(2-(3-(S)-(3-(7-氯-2-喹啉基)-乙烯基)苯基)-3-羟基丙基)-苯基-2-丙醇的方法。
• [EN] MONTELUKAST BENZHYDRYL PIPERAZINE SALTS AND PROCESS FOR PREPARATION THEREOF<br/>[FR] SELS DE PIPÉRAZINE DE BENZHYDRYLE DE MONTÉLUKAST ET LEUR PROCÉDÉ DE PRÉPARATION
  申请人：TORRENT PHARMACEUTICALS LTD

  公开号：WO2009113087A1

  公开（公告）日：2009-09-17

  The invention relates to Benzhydryl piperazine salts of [R-(E)] -1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(1 -hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid represented by the formula (III). Furthermore, the invention relates to the use of Benzhydryl piperazine salts of [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid represented by the formula (III) for the preparation of substantially pure [R-(E)]-1-[[[1-[3-[2-(7-chloro-2-quinolinyl) ethenyl]phenyl] -3 -[2-(1-hydroxy-1- methylethyl) phenyl] propyl] thio] methyl] cyclopropane acetic acid or its alkali, salts and pharmaceutical composition comprising the same.

  本发明涉及由式（III）表示的[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸的苯甲基哌嗪盐。此外，本发明还涉及使用由式（III）表示的苯甲基哌嗪盐[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸或其碱盐制备基本纯的[R-(E)]-1-[[[1-[3-[2-(7-氯-2-喹啉基)乙烯基]苯基]-3-[2-(1-羟基-1-甲基乙基)苯基]丙基]硫]甲基]环丙烷乙酸或其碱盐和包含它们的药物组合物的用途。
• BICYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF ANDROGEN RECEPTOR ASSOCIATED CONDITIONS-155
  申请人：Bradbury Robert Hugh

  公开号：US20100016279A1

  公开（公告）日：2010-01-21

  The invention concerns bicyclic compounds of Formula I wherein the integers X 1 , X 2 , X 3 , Ring A, R 4 , R 5 and m are as defined in the description. The present invention also relates to processes for the preparation of such compounds, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the prevention or treatment of androgen-receptor associated conditions.

  本发明涉及公式I的双环化合物，其中整数X1、X2、X3、环A、R4、R5和m如描述中所定义。本发明还涉及制备这种化合物的方法、包含它们的制药组合物以及它们在制造用于预防或治疗与雄激素受体相关疾病的药物中的应用。